Apr. 20 at 3:04 AM
$EVMN There was a flurry of activity Friday as the entire C-suite—including CEO Luis Pena, CFO Kyle Carver, and CMO Eugene Bauer—all received massive stock option grants on the same day. These were not open-market buys. They were compensation-related grants with an exercise price of
$26.77.
Large-scale grants to the entire executive team at once usually signal that the board wants management fully aligned with shareholders before a major "binary event" (a high-stakes clinical result). The S-1 filed on Friday isn't a standard IPO or a new offering where the company gets more cash. It is a Resale Registration Statement. It covers roughly 4.5 million shares held by existing stockholders. These shares come from the
$125 million private placement that closed back in February 2026.The company isn't raising new money; they are fulfilling a promise to those private investors to make their shares "liquid." Once this S-1 becomes effective, those investors can sell their shares on the open market.
